Aspirin in essential thrombocythemia: Status quo and quo vadis

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 4, 1997, Pages 371-377

  Griesshammer, Martin ^a   Bangerter, Markus ^a   Van Vliet, Huub H D M ^b   Michiels, Jan J ^c,d  

^a UNIVERSITY OF ULM   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d Goodheart Institute   (Netherlands)

Author keywords

Arterial thrombosis; Aspirin; Erythromelalgia; Essential thrombocythemia; Transient ischemic attacks (TIAs); Treatment

Indexed keywords

ACETYLSALICYLIC ACID;

ARTERY THROMBOSIS; BLEEDING TENDENCY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; ERYTHROMELALGIA; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTHEMIA; VISUAL IMPAIRMENT;

EID: 0030814715     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996111     Document Type: Review

References (44)

1. Van Genderen PJJ, JJ Michiels: Primary thrombocythemia: Diagnosis, clinical manifestations and management. Ann Hematol 67: 57-62, 1993.
2. Rozman C, M Giralt, E Feliu, D Rubio, MT Cortes: Life expectancy of patients with chronic non-leukemic myeloproliferative disorders. Cancer 67:2658-2663, 1991.
3. Cortelazzo S, G Finazzi, M Ruggeri, O Vestri, M Galli, F Rodeghiero, T Barbui: Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332:1132-1136, 1995.
4. Millard FE, CS Hunter, M Anderson, MJ Edelmann, MP Kosty, GA Luiken, GG Marino: Clinical manifestations of essential thrombocythemia in young adults. Am J Hematol 33:27-31, 1990.
5. Weinfeld A, B Swolin, J Westin: Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Hematol 52:134-139, 1994.
6. Patrono C: Aspirin as an antiplatelet drug. N Engl J Med 330: 1287-1294, 1994.
7. Mitus AJ, AL Schafer: Thrombocytosis and thrombocythemia. Hematol Oncol Clin North Am 4:157-178, 1990.
8. Michiels JJ, PJ Koudstaal, AH Mulder, HHDM van Vliet: Transient neurological and ocular manifestations in primary thrombocythemia. Neurology 43:1107-1110, 1993.
9. Tartaglia AP, JD Goldberg, PD Berk, LR Wasserman: Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin Hematol 23:172-176, 1986.
10. Van de Pette, AV Prochazka, TC Pearson, AK Singh, ER Dickson, G Wetherley-Mein: Primary thrombocythemia treated with busulphan. Br J Haematol 62:229-237, 1986.
11. Belluci S, M Janvier, G Tobelem, G Flandrin, Y Charpak, R Berger, M Boiron: Essential thrombocythemias: Clinical evolutionary and biological data. Cancer 58:2440-2447, 1986.
12. Grossi A, S Rosseti, AM Vannucchi, D Rafanelli, PR Ferrini: Occurrence of haemorrhagic and thrombotic events in myeloproliferative disorders: A retrospective study of 108 patients. Clin Lab Haematol 10:167-175, 1988.
13. Hehlmann R, M Jahn, B Baumann, W Kopcke: Essential thrombocythemia: Clinical characteristics and course of 61 cases. Cancer 61:2487-2496, 1988.
14. Lahuerta-Palacios JJL, R Bornstein, FJ Fernandez-Debora, E Gutierrez-Rivas, MC Ortiz, S Larregla, L Galandre, J Montreo-Castillo: Controlled and uncontrolled thrombocytosis. Its clinical role in thrombocythemia. Cancer 61:1207-1212, 1988.
15. Cortelazzo S, P Viero, G Finazzi, A D'Emilio, F Roheghiero, T Barbui: Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 8:556-562, 1990.
16. Fenaux P, M Simon, MT Caulier, JL Lai, J Goudemand: Clinical course of essential thrombocythemia. Cancer 66:549-556, 1990.
17. Colombi M, F Radaelli, L Zocchi, AT Maiolo: Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 67:2926-2930, 1991.
18. Watson KV, M Key: Vascular complications of essential thrombocythemia: A link to cardiovascular risk factors. Br J Haematol 83: 198-203, 1993.
19. Michiels JJ, PJJ van Genderen, J Lindemans, HHDM van Vliet: Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. Leuk Lymphoma 22(Suppl 1):47-56, 1996.
20. Murphy S, H Iland, J Laszlo: Essential thrombocythemia, an interim report from the Polycythemia Vera Study Group. Semin Hematol 23:177-182, 1986.
21. Michiels JJ, J Abels, J Steketee, HHDM van Vliet, VD Vuzevski: Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann Intern Med 102: 466-471, 1985.
22. Kurzrock R, PR Cohen: Erythromelalgia and myeloproliferative disorders. Arch Intern Med 149:105-109, 1989.
23. Michiels JJ, J Lindemans, HHDM van Vliet, J Abels: Survival kinetics of platelet and fibrinogen in thrombocythemia related to erythromelalgia. Br J Haematol 50:691, 1982.
24. van Genderen PJJ, JJ Michiels, J Lindemans, R van Strik, HHDM van Vliet: Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. Thromb Haemostas 73: 210-214, 1995.
25. Preston FE, IG Emmanuel, DA Winfield, RG Malia: Essential thrombocythemia and peripheral gangrene. Br Med J 3:548-552, 1974.
26. Preston FE: Aspirin, prostaglandins, and peripheral gangrene. Am J Med 74(Suppl):55-60, 1983.
27. Jabaily J, HJ Iland, J Laszlo, EW Massey, GB Faguet, J Briere, A Landaw, AV Pisciotta: Neurologic manifestations of essential thrombocythemia. Ann Intern Med 99:513-518, 1983.
28. Michiels JJ, PJJ van Genderen, PHP Jansen, PJ Koudstaal: A typical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders. Leuk Lymphoma 22(Suppl 1):65-70, 1996.
29. Bernstein A, F Simon, EL Rothfeld, FB Cohen: Primary thrombocytosis and anginal syndrome. Am J Cardiol 16:351-354, 1960.
30. Barr I, P Cohen, A Berken, B Lown: Thrombocythemia and myocardial ischemia with normal coronary angiogram. Arch Intern Med 134:528-533, 1974.
31. Douste-Blazy P, MJ Taudou, M Delay, J Pris, P Sie, L Ribaut, F Galinier, F Bernadet: Essential thrombocythemia and recurrent myocardial infarction. Lancet 2:992, 1984.
32. Scheffer MG, JJ Michiels, ML Simoons, JRTC Roelandt: Thrombocythemia and coronary artery disease. Am Heart J 122:573-576, 1991.
33. Louwerenburg JW, MJ Suttorp, JH Kingma: Aspirin withdrawal in a patient with essential thrombocythemia: Possible cause of myocardial infarction. Am J Med 83:1175, 1997.
34. Beressi AN, A Tefferi, MN Silverstein, RM Petitt, HC Hoagland: Outcome analysis of 34 pregnancies in women with essential thrombocythemia. Arch Intern Med 155:1217-1222, 1995.
35. Griesshammer M, H Heimpel, TC Pearson: Essential thrombocythemia and pregnancy. Leuk Lymphoma 22(Suppl 1):57-63. 1996.
36. Van Genderen PJJ, IS Lucas, R van Strik, VD Vuzevski, FJ Prins, HHDM van Vliet, JJ Michiels. Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial damage but not by thrombin generation. Thromb Haemostas 76:333-338, 1996.
37. Landolfi R, G Ciabattoni, P Patrignani, MAL Castellana, E Pogliani, B Bizzi, C Patrono: Increased thromboxane biosynthesis in patients with polycythemia vera: Evidence for aspirin-suppressible platelet activation in vivo. Blood 80:1965-1971, 1992.
38. Rocca B, G Ciabattoni, R Tartaglione, S Cortelazzo, T Barbui, C Patrono, R Landolfi: Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemostas 74:1225-1230, 1995.
39. Landolfi R, C Patrono: Aspirin in polycythemia vera and essential thrombocythemia: Current facts and perspectives. Leuk Lymphoma 22(Suppl 1):83-86, 1996.
40. Van Genderen PJJ, U Budde, JJ Michiels, R van Strik, HHDM van Vliet: The reduction of large von Willebrand factor multimers in plasma in essential thrombocythaemia is related to the platelet count. Br J Haematol 93:962-965, 1996.
41. Barbui T, M Buelli, S Cortelazzo, P Viero, G de Gaetano: Aspirin and risk of bleeding in patients with thrombocythemia. Am J Med 83:265-268, 1987.
42. Van Genderen PJJ, PGH Mulder, M Waleboer, D van de Moesdijk, JJ Michiels: Prevention and treatment of thrombotic complications in essential thrombocythaemia: Efficacy and safety of aspirin. Br J Haematol. 97:179-84, 1997.
43. The SALT Collaborative Group: Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 338:1345-1349, 1991.
44. Finazzi G, U Budde, JJ Michiels: Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes. Leuk Lymphoma 22(Suppl 1):71-78, 1996.